Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395512 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 655
- Enrollment target
NCT00395512: Completed Phase 3 study, sponsored by Takeda.
NCT00395512 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 655 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00395512, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 655 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
Primary Outcome
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Alogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 655 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
What the finished NCT00395512 record still lists
NCT00395512 is an interventional study that assigns participants to a tested intervention. The registered 655 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00395512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00395512 about?
NCT00395512 is a clinical study titled "Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
What is the current status of trial NCT00395512?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 655 participants. The study started on 2006-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00395512?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00395512?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00395512's enrollment target sits among peer trials
655 565th of 2000 higher than 1,434 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07145515 · 655 participants · NA
Enhancing Heart Allograft Function With the OCS Heart System Trial
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia